Are you Dr. Gibbons?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 91 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Don Gibbons Jr., MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2004 - 2006
Albert Einstein College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2007 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Clinical Trials
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). Start of enrollment: 2014 Mar 24
- MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2018 May 01
Publications & Presentations
PubMed
- 2 citationsA Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01 - Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples.Nejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez Ruiz, Wei Lu, Khaja Khan
Research Square. 2025-01-17 - Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.Marcelo V Negrao, Alvaro G Paula, David Molkentine, Laura Hover, Monique Nilsson
Clinical Cancer Research. 2025-01-13
Press Mentions
MD Anderson Research Highlights: SITC 2024 Special EditionNovember 9th, 2024- MD Anderson Research Highlights for August 11, 2021August 11th, 2021
Meet 2019 STAT Wunderkind Limo Chen, Ph.D., of MD Anderson Cancer CenterJanuary 8th, 2020- Join now to see all
Grant Support
- Notch And Stem Cells In Lung Cancer Treated With Erlotinib PLUS Notch Inhibitor.National Cancer Institute2011–2012
- Microrna-200 Family Regulation By The Apical-Basal Polarity Complexes In EMT AndNational Cancer Institute2010–2011
Professional Memberships
- Member
